Combination therapy with ezetimibe [Zetia, Ezetrol] plus fenofibrate is effective in patients with mixed hyperlipidaemia, according to a study presented at the Scientific Sessions of the American Heart Association [New Orleans, US; November 2004]. In this study, which involved > 600 patients, treatment with ezetimibe plus fenofibrate produced significant reductions in levels of LDL-cholesterol, total cholesterol and non-HDL-cholesterol, compared with fenofibrate monotherapy. Favourable effects of the combination were observed on lipoprotein subclasses and LDL-cholesterol subclasses. Furthermore, the combination was well tolerated, and had a similar tolerability profile to that of fenofibrate monotherapy.